GemPharmatech (SH:688046) Xinda Securities·2025-10-28 10:34Investment Rating - The report assigns a "Buy" rating for the stock of YaoKang Bio (688046) based on its performance and growth potential [11]. Core Insights - YaoKang Bio has shown a quarterly acceleration in performance, with a revenue of 576 million yuan for the first three quarters of 2025, representing a year-on-year growth of 12.92%. The net profit attributable to the parent company reached 110 million yuan, up 11.90% year-on-year, and the non-recurring net profit was 93 million yuan, reflecting a significant increase of 29.21% [1][2]. - The functional efficacy business is identified as a key driver of growth, with a revenue of 87.93 million yuan in the first half of 2025, marking a year-on-year increase of 23.69%. New orders have surged by over 40% year-on-year, indicating strong demand [2]. - The establishment of a wholly-owned subsidiary, NiuMai Bio, aims to cultivate a fully human antibody platform, which is expected to become a significant growth engine for the company. The subsidiary has completed comprehensive validation of various human antibody models and is actively engaged in innovative antibody research across multiple therapeutic areas [3]. Financial Performance Summary - For the fiscal years 2025 to 2027, the projected revenues are 790 million yuan, 950 million yuan, and 1.144 billion yuan, respectively, with corresponding net profits of 143 million yuan, 177 million yuan, and 221 million yuan. The earnings per share (EPS) are expected to be 0.35 yuan, 0.43 yuan, and 0.54 yuan, with price-to-earnings (P/E) ratios of 48.79, 39.49, and 31.57 [4][5].